Addition of boceprevir to peg-interferon/ribavirin in HIV-HCV-genotype-1-coinfected, treatment-experienced patients: Efficacy, safety, and pharmacokinetics data from the ANRS HC27 study

HIV Clinical Trials

Volumn 17, Issue 2, 2016, Pages 63-71

  Poizot Martin, Isabelle ^a,b   Bellissant, Eric ^c,d   Garraffo, Rodolphe ^e   Colson, Philippe ^a,f   Piroth, Lionel ^g   Solas, Caroline ^a,h   Renault, Alain ^c,d   Bourlière, Marc ⁱ   Halfon, Philippe ^j   Ghosn, Jade ^k,l   Alric, Laurent ^m   Naqvi, Alissa ^e   Carrieri, Patrizia ^b,n   Molina, Jean Michel ^k  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIV   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

^e UNIVERSITÉ CÔTE D'AZUR   (France)

^f INSERM   (France)

^g UNIV BOURGOGNE FRANCHE COMTÉ   (France)

^h University of the Mediterranean Aix Marseille II   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^j EUROPEAN HOSPITAL   (France)

^k UNIVERSITÉ PARIS DESCARTES   (France)

^l UNIVERSITÉ PARIS SACLAY   (France)

^m UNIVERSITÉ PAUL SABATIER   (France)

ⁿ OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; EMTRICITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA2B; RALTEGRAVIR; RIBAVIRIN; TENOFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PEGINTERFERON ALPHA2A; PROLINE; RECOMBINANT PROTEIN;

ACUTE PYELONEPHRITIS; ADD ON THERAPY; ADULT; ANEMIA; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LEUKONEUTROPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MIXED INFECTION; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEPSIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COINFECTION; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84963795098     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1080/15284336.2015.1135553     Document Type: Article

References (15)

1. Lacombe K. Hepatitis C, from screening to treatment, a revolution. J Int AIDS Soc. 2014;17:19499.
2. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. Mar. 2012;56:718-726.
3. Colson P, Purgus R, Borentain P, Gérolami R. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors. J Clin Virol. 2012;53:178-180.
4. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
5. Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49:1853-1860.
6. Stanke-Labesque F, Loustaud-Ratti V, Babany G, Gagnieu MC, Marquet P. Ribavirin therapeutic drug monitoring: why, when and how? Fundam Clin Pharmacol. 2010;24:401-406.
7. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. Hepatology. 2007;46:971-981.
8. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593.
9. de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis. 2013;56:300-306.
10. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-1217.
11. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597-605.
12. Mandorfer M, Steiner S, Schwabl P, et al. Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: The HIVCOBOC-RGT study. J Infect Dis. 2015;211:729-735
13. Jacobson IM, Pawlotsky JM, Afdhal NH, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 2012;19:1-26.
14. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59:434-441.
15. Manzano-Robleda Mdel C, Ornelas-Arroyo V, Barrientos-Gutierrez T, Mendez-Sanchez N, Uribe M, Chavez-Tapia NC. Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. Ann Hepatol. 2015;14:46-57.